论文部分内容阅读
目的:观察依达拉奉联合低分子肝素治疗急性脑梗死的临床疗效。方法:将110例急性脑梗死患者随机分为治疗组、对照组各55例。治疗组用依达拉奉联合低分子肝素治疗,对照组用低分子肝素治疗。治疗前后神经功能缺损评分并判定疗效。结果:治疗组患者的神经功能缺损改善情况明显优于对照组(P<0.05),临床疗效两组间有显著差异(P<0.01)。结论:依达拉奉联合低分子肝素治疗急性脑梗死疗效显著。
Objective: To observe the clinical efficacy of edaravone combined with low molecular weight heparin in the treatment of acute cerebral infarction. Methods: 110 patients with acute cerebral infarction were randomly divided into treatment group and control group of 55 cases. The treatment group with Edaravone combined with low molecular weight heparin treatment, the control group with low molecular weight heparin treatment. Before and after treatment neurological deficit score and determine the efficacy. Results: The improvement of neurological deficits in the treatment group was significantly better than that in the control group (P <0.05). The clinical efficacy was significantly different between the two groups (P <0.01). Conclusion: Edaravone combined with low molecular weight heparin treatment of acute cerebral infarction significant effect.